Trial Profile
Bevacizumab in Combination with Capecitabine/Irinotecan or Capecitabine/Oxaliplatin is Effective and Safe as First-Line Therapy for Metastatic Colorectal Cancer: a Randomized Phase II Study of the Aio Colorectal Study Group
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 09 Nov 2010 New trial record
- 27 Oct 2010 Results were presented at the 18th United European Gastroenterology Week.